InvestorsHub Logo
Followers 1
Posts 9
Boards Moderated 0
Alias Born 08/10/2016

Re: coldasice post# 10935

Wednesday, 11/15/2017 10:00:11 AM

Wednesday, November 15, 2017 10:00:11 AM

Post# of 12137
Thanks Coldasice for your reference, I feel honoured. However, I believe I do understand the situation with CryoPort, because I have seen how the integration of IT has developed over the years to such an extent that, especially a Pharmaceutical Business, just cannot exist without a full and complete Integration of Information relating to a product from ist initial creation to ist Arrival at the customer/Patient.

I am a retired IT Person who, back in the early 70's, was involved on the development of a product-batch recall System for a pharmaceutical Company. With this system the Company was able to trace all its' individual ingredients (for an end product) back to its' basic suppliers and this going back over many years. In the meantime this is now a standard basic process. However, moving on, but in a somewhat similar manner (but also far more complex) a company in the CAR-T type of Business must be able to conclusively prove that a Patient has not only received their original blood but that during ist time out of the patients body it has been fully managed according to all defined handling / temperature requirements.

Clearly, CryoPort have this proven and established infrastructure in place and consequently, following the principle that a pharmaceutical Company is specialised in researching and creating pharmaceuticals, the pharmacetical companies turn to another reliable specialist for the non-specific pharmaceutical logistical requirements.

The particular Beauty of this CryoPort Business concept is that, while the individual pharma companies handle all the FDA-related activities, etc., CyroPort just gets carried along and is automatically included in the various phases upto and including approval. Consequently, an FDA-approval effectively guarantees CyroPort's inclusion, since a change of the key logistics element could potentially have an negative impact on the original approval (I believe it would be effectively just like a change to a GMP conformance requirement). Therefore a pharma company with an approved product would want to have very strong reasons to even attempt to change such a key element of their logistcs.

For me, CyroPort have basically achieved a significant "Moat around their Castle", to coin a Phrase! (I believe this was a significant Investment principle from ca. 20-30 years back!! This is for me a major justification for my Long-term investment in this Company.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYRX News